Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Filtros aplicados
Base de dados
Intervalo de ano de publicação
1.
Clin. transl. oncol. (Print) ; 26(2): 398-413, feb. 2024.
Artigo em Inglês | IBECS | ID: ibc-230185

RESUMO

Introduction ABL2 contributes to the oncogenic potential of cancers, pointing to its inhibition as a possible strategy against malignant diseases. Bioinformatics prediction of upstream effector miR-30a-5p for ABL2 allowed us to hypothesize and then validate mechanistic actions of miR-30a-5p in lung adenocarcinoma (LUAD). Materials and methods The ABL2 expression in LUAD was analyzed in the TCGA data, clinical samples, and cell lines. The shRNA-mediated silencing of ABL2 was introduced to illustrate its effect on malignant phenotypes of LUAD cells. The binding affinity between ABL2 and miR-30a-5p was verified by luciferase activity and RNA pull-down assay. Ectopic expression, knockdown methods, and PI3K inhibitor LY294002 were used to investigate their effects on in vitro biological characteristics and in vivo tumor growth of LUAD cells. Using nude mouse lung adenocarcinoma in situ and brain metastasis models to validate the inhibitory effect of miR-30a-5p on LUAD by regulating the ABL2/PI3K/AKT signaling axis. Results High expression of ABL2 and poor expression of miR-30a-5p were noticed in LUAD tissues and cell lines. Importantly, miR-30a-5p was demonstrated to target and downregulate ABL2, subsequently inactivating the PI3K/AKT pathway. miR-30a-5p inhibited the malignant phenotypes of LUAD cells by inhibiting ABL2 expression and inactivating the PI3K/AKT pathway. For in vivo experiments, miR-30a-5p was substantiated to thwart tumor tumorigenesis by regulating the ABL2/PI3K/AKT axis. In addition, miR-30a-5p suppresses the occurrence and development of in situ lung cancer and brain metastasis via the ABL2/PI3K/AKT signaling pathway. Conclusion This study underscores the inhibitory role of miR-30a-5p in LUAD through the ABL2/PI3K/AKT axis, which may be a viable target for LUAD treatment (AU)


Assuntos
Animais , Camundongos , Adenocarcinoma de Pulmão/genética , Neoplasias Encefálicas , Carcinoma de Mama in situ , Neoplasias Pulmonares , MicroRNAs/genética , Camundongos Nus , Proteínas Proto-Oncogênicas c-akt
2.
Rev. senol. patol. mamar. (Ed. impr.) ; 33(3): 88-93, jul.-sept. 2020. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-197291

RESUMO

OBJETIVOS: Revisión y análisis de los casos de lesiones papilares intraductales mamarias diagnosticados en nuestro centro entre enero del 2007 y diciembre del 2017. Estudiar la asociación de las lesiones papilares con el cáncer de mama. PACIENTES Y MÉTODOS: Estudio descriptivo retrospectivo utilizando la base de datos de Anatomía Patológica. Se incluyó a 135 pacientes que en el periodo descrito tuvieron un diagnóstico anatomopatológico de lesión papilar (papiloma benigno aislado, papilomatosis múltiple, papiloma con carcinoma in situ, papiloma con atipia o carcinoma papilar intraductal). Las variables principales a analizar fueron la edad de las pacientes, las pruebas diagnósticas realizadas, la presencia de lesiones de mayor grado asociadas a la lesión papilar y el desarrollo de neoplasia de mama durante el seguimiento. RESULTADOS: La edad media de las pacientes fue de 50 años. La ductoscopia demostró ser una prueba con alta sensibilidad diagnóstica (88%). En 12 casos (9%) existía carcinoma en la lesión papilar o en sus alrededores (8 carcinomas in situ y 4 infiltrantes) y en 4 casos (3%) encontramos hiperplasia atípica asociada. Con un seguimiento medio de 34 meses, 6 pacientes tuvieron una recidiva en forma de lesión papilar (una papilomatosis múltiple y 5 papilomas), 3 pacientes recidivaron en forma de lesión neoplásica y una paciente desarrolló una neoplasia contralateral. CONCLUSIONES: Ante la sospecha de una lesión papilar y la presencia de secreción por el pezón, debemos considerar la realización de una ductoscopia por su alta sensibilidad. La alta incidencia de una neoplasia asociada a la lesión papilar o su aparición durante el seguimiento justifica su exéresis quirúrgica completa y un seguimiento estricto


OBJECTIVES: To provide a review and analysis of cases of intraductal papillary breast lesions diagnosed at our centre between January 2007 and December 2017, and to study the association between papillary lesions and breast cancer. PATIENTS AND METHODS: We performed a retrospective descriptive study using the pathology database of our centre. We included 135 patients with a pathological diagnosis of papillary lesion (isolated benign papilloma, multiple papillomatosis, papilloma with carcinoma in situ, papilloma with atypia or intraductal papillary carcinoma). The main variables were age, the diagnostic procedures performed, the presence of higher-grade lesions associated with the papillary lesion, and the development of breast neoplasms during follow-up. RESULTS: The patients' mean age was 50 years. Ductoscopy had high sensitivity (88%). Twelve patients (9%) had carcinomas on the papillary lesion or its surrounding areas (8 carcinomas in situ and 4infiltrating carcinomas) and 4 patients (3%) had associated atypical hyperplasia. With a mean follow-up of 34 months, 6 patients had recurrence as a papillary lesion (one multiple papillomatosis and 5papillomas), 3 patients relapsed with a neoplastic lesion, and one patient developed a contralateral neoplasm. CONCLUSIONS: In the presence of a suspected papillary lesion and nipple secretion, ductoscopy should be considered due to its high sensitivity. The high incidence of neoplasms associated with papillary lesions or their development during follow-up justifies their complete surgical excision and strict follow-up


Assuntos
Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Carcinoma Intraductal não Infiltrante/patologia , Carcinoma Papilar/patologia , Neoplasias da Mama/patologia , Carcinoma de Mama in situ/patologia , Neoplasias da Mama/epidemiologia , Carcinoma de Mama in situ/epidemiologia , Derrame Papilar/citologia , Estudos Retrospectivos , Endoscopia/métodos , Mamografia/métodos , Biópsia/métodos , Mastectomia/métodos , Margens de Excisão
3.
Rev. senol. patol. mamar. (Ed. impr.) ; 32(1): 26-31, ene.-mar. 2019. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-187030

RESUMO

El carcinoma mioepitelial de mama (o mioepitelioma maligno) es un tumor poco frecuente compuesto exclusivamente por células mioepiteliales malignas. Su diagnóstico supone un reto, y viene dado por los hallazgos anatomopatológicos apoyados por las técnicas de inmunohistoquímica. Presentamos un caso clínico y revisión bibliográfica


Myoepithelial carcinoma of the breast (or malignant myoepithelioma) is a rare tumor composed exclusively of malignant myoepithelial cells. Its diagnosis is a challenge and is reached through pathological findings supported by immunohistochemical techniques. We present a case report and a review of the literature


Assuntos
Humanos , Feminino , Idoso de 80 Anos ou mais , Mioepitelioma/patologia , Neoplasias da Mama/patologia , Biópsia com Agulha de Grande Calibre/métodos , Carcinoma Ductal de Mama/patologia , Carcinoma de Mama in situ/patologia , Diagnóstico Diferencial , Vimentina/isolamento & purificação , Queratinas/isolamento & purificação , Biomarcadores Tumorais/análise
4.
Clin. transl. oncol. (Print) ; 21(1): 18-30, ene. 2019. tab
Artigo em Inglês | IBECS | ID: ibc-183341

RESUMO

Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around 20-30% of patients will relapse despite appropriate locoregional and systemic therapies. A better knowledge of this disease is improving our ability to select the most appropriate therapy for each patient with a recent diagnosis of an early stage breast cancer, minimizing unnecessary toxicities and improving long-term efficacy


No disponible


Assuntos
Humanos , Neoplasias da Mama/diagnóstico , Quimioterapia Adjuvante/métodos , Terapia Neoadjuvante/métodos , Carcinoma Ductal de Mama/terapia , Carcinoma de Mama in situ/terapia , Neoplasias da Mama/terapia , Detecção Precoce de Câncer/métodos , Genômica/métodos , Estadiamento de Neoplasias/métodos , Mastectomia/métodos , Genes BRCA1 , Genes BRCA2 , Valor Preditivo dos Testes , Padrões de Prática Médica
5.
Prog. obstet. ginecol. (Ed. impr.) ; 61(5): 481-486, sept.-oct. 2018. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-175083

RESUMO

Presentamos el caso de una paciente de 45 años, con antecedentes familiares de cáncer de mama y sin antecedentes personales de interés, con una tumoración de mama de corta duración. El diagnóstico fue un Carcinoma metaplásico fusocelular de alto grado con diferenciación de células tipo osteoclástico. Se realizó tratamiento quimioterápico neoadyuvante, quirúrgico y quimioterapia adyuvante. Presentó diseminación metastásica 3 meses después de la cirugía y a los 8 meses de la aparición de la primera metástasis fue éxitus. Dada la baja incidencia, difícil manejo y mal pronóstico, consideramos necesario elaborar una revisión bibliográfica sobre este tipo de neoplasia de mama


We report the case of a 45-year-old patient patient with a family history of breast cancer and no relevant personal history, with a short-term breast tumor. The diagnosis was a high-grade fusocellular metaplastic carcinoma with osteoclast-like cell differentiation. Neoadjuvant chemotherapy, surgery and adjuvant chemotherapy were performed. He presented metastatic dissemination 3 months after surgery and at 8 months after the onset of the first metastasis she died. Given the rarity of this entity, difficult management and poor prognosis, we consider that a literatura review of this type of breast tumor


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Metaplasia/patologia , Neoplasias da Mama/patologia , Carcinoma de Mama in situ/patologia , Estadiamento de Neoplasias , Terapia Neoadjuvante/métodos , Metástase Neoplásica/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...